DaVita studies suggest expanded hemodialysis preserves albumin levels

By Public Technologies
  • DaVita will present seven studies at American Society of Nephrology Kidney Week 2026, with presentations scheduled for Oct. 22-24.
  • Two expanded hemodialysis studies suggest the therapy could benefit a broad patient population while preserving albumin levels.
  • A peritoneal dialysis study links treatment completion following hospital discharge to reduced cumulative hospitalizations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DaVita Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610150900PR_NEWS_USPR_____LA72930) on October 15, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.